Table 7.
Average monthly pharmaceutical antineoplastic expenditure per breast cancer patient (EUR) by intrinsic molecular subtypes during the 2010–2019 study period.
| Intrinsic Molecular Subtype | Year | Pharmaceutical Expenditure |
Patients | Cost per Patient per Month |
|---|---|---|---|---|
| HER2+ | 2010 | €1,604,633 | 118 | €2042 |
| 2011 | €1,830,649 | 129 | €2094 | |
| 2012 | €2,161,834 | 149 | €2108 | |
| 2013 | €1,945,750 | 148 | €1901 | |
| 2014 | €2,420,214 | 159 | €2306 | |
| 2015 | €2,981,295 | 190 | €2120 | |
| 2016 | €4,059,094 | 198 | €2500 | |
| 2017 | €3,302,505 | 194 | €2402 | |
| 2018 | €3,561,315 | 191 | €2620 | |
| 2019 | €4,259,045 | 216 | €2661 | |
| Luminal | 2010 | €122,325 | 51 | €557 |
| 2011 | €56,774 | 66 | €210 | |
| 2012 | €46,715 | 48 | €257 | |
| 2013 | €155,623 | 139 | €262 | |
| 2014 | €328,188 | 216 | €273 | |
| 2015 | €271,211 | 214 | €304 | |
| 2016 | €428,177 | 255 | €317 | |
| 2017 | €518,371 | 275 | €332 | |
| 2018 | €1,229,130 | 266 | €784 | |
| 2019 | €2,005,265 | 317 | €881 | |
| Triple negative | 2010 | €36,943 | 17 | €421 |
| 2011 | €12,391 | 20 | €168 | |
| 2012 | €41,988 | 11 | €757 | |
| 2013 | €64,363 | 52 | €255 | |
| 2014 | €121,186 | 70 | €317 | |
| 2015 | €160,960 | 83 | €328 | |
| 2016 | €154,562 | 70 | €443 | |
| 2017 | €163,439 | 69 | €328 | |
| 2018 | €144,850 | 72 | €489 | |
| 2019 | €143,413 | 78 | €386 | |
| Total | 2010–2019 | €34,332,210 | 2308 | €1222 |